🇺🇸 Azithromycin 250 mg in United States

83 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Diarrhoea — 11 reports (13.25%)
  2. Nausea — 11 reports (13.25%)
  3. Dizziness — 10 reports (12.05%)
  4. Abdominal Pain — 9 reports (10.84%)
  5. Dyspnoea — 9 reports (10.84%)
  6. Abdominal Pain Upper — 8 reports (9.64%)
  7. Rash — 7 reports (8.43%)
  8. Headache — 6 reports (7.23%)
  9. Hypersensitivity — 6 reports (7.23%)
  10. Urticaria — 6 reports (7.23%)

Source database →

Azithromycin 250 mg in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Azithromycin 250 mg approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Azithromycin 250 mg in United States?

Centre Hospitalier Universitaire, Amiens is the originator. The local marketing authorisation holder may differ — check the official source linked above.